公开(公告)号：US20210393600A1

公开(公告)日：2021-12-23

申请号：US17047247

申请日：2019-04-15

Applicant: Merck Sharp & Dohme Corp.

Inventor： Liangqin Guo ,  Hongjun Zhang ,  Ping Chen ,  Dane Clausen ,  Xavier Fradera ,  Yongxin Han ,  Shuwen He ,  Xianhai Huang ,  Alexander Pasternak ,  Qinglin Pu ,  Li Xiao ,  Feng Ye

IPC: A61K31/44 ,  A61K45/06 ,  C07C237/22 ,  C07C255/60 ,  C07D213/75 ,  C07C271/36 ,  C07C233/78 ,  C07C271/24 ,  C07C233/79 ,  C07D213/81 ,  C07D271/06 ,  C07D239/28 ,  C07D215/48 ,  C07C275/30 ,  C07C275/28 ,  C07D239/42 ,  C07D305/06 ,  C07D261/08 ,  C07D471/04 ,  C07D261/20 ,  C07D209/34 ,  C07D277/56 ,  C07D217/02 ,  C07D231/14 ,  C07D237/28 ,  C07D241/24 ,  C07D217/26 ,  A61K31/167 ,  A61K31/27 ,  A61K31/4245 ,  A61K31/47 ,  A61K31/17 ,  A61K31/505 ,  A61K31/337 ,  A61K31/437 ,  A61K31/42 ,  A61K31/426 ,  A61K31/472 ,  A61K31/415 ,  A61K31/4965

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US20210198190A1

公开(公告)日：2021-07-01

申请号：US17057921

申请日：2019-05-28

Applicant: Merck Sharp & Dohme Corp.

Inventor： Shuwen He ,  Dane Clausen ,  Liangqin Guo ,  Yongxin Han ,  Xianhai Huang ,  Alexander Pasternak ,  Qinglin Pu ,  Dong Xiao ,  Li Xiao ,  Feng Ye ,  Hongjun Zhang

IPC: C07C271/14 ,  C07D239/42 ,  C07D237/34 ,  C07D241/20 ,  C07D239/94 ,  C07D213/74 ,  C07D471/04 ,  A61P35/00

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US10995085B2

公开(公告)日：2021-05-04

申请号：US16819325

申请日：2020-03-16

Applicant: Merck Sharp & Dohme Corp.

Inventor： Yongxin Han ,  Abdelghani Achab ,  Yongqi Deng ,  Xavier Fradera ,  Craig Gibeau ,  Brett A. Hopkins ,  Derun Li ,  Kun Liu ,  Meredeth A. McGowan ,  Nunzio Sciammetta ,  David Sloman ,  Catherine White ,  Hongjun Zhang ,  Hua Zhou

IPC: C07D405/10 ,  A61K31/4523 ,  A61K45/06 ,  C07D471/04 ,  A61K31/437 ,  A61K31/506 ,  A61K31/4155 ,  C07D305/08 ,  A61K31/337 ,  C07D417/10 ,  A61K31/427 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/4184 ,  C07D405/14 ,  A61K31/444 ,  A61K31/513 ,  C07D413/04 ,  C07D401/04 ,  C07D213/56 ,  A61K31/4418 ,  C07D417/14 ,  A61K31/501 ,  C07D241/12 ,  A61K31/4965 ,  A61K31/4427 ,  C07D263/32 ,  A61P37/00 ,  C07D231/12 ,  A61P35/00 ,  C07D413/10 ,  C07D401/12 ,  C07D405/04 ,  A61P31/00 ,  C07D209/46 ,  C07D413/14

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US20200231606A1

公开(公告)日：2020-07-23

申请号：US16326408

申请日：2017-08-24

Applicant: Merck Sharp & Dohme Corp.

Inventor： Kun Liu ,  Abdelghani Achab ,  Purakkattle Biju ,  Timothy A. Cernak ,  Yongqi Deng ,  Xavier Fradera ,  Liangqin Guo ,  Yongxin Han ,  Shuwen He ,  Joseph Kozlowski ,  Derun Li ,  Guoqing Li ,  Qinglin Pu ,  Zhi-Cai Shi ,  Wensheng Yu ,  Hongjun Zhang

IPC: C07F5/02 ,  C07D271/08 ,  C07D413/12

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US10689369B2

公开(公告)日：2020-06-23

申请号：US16356172

申请日：2019-03-18

Applicant: Merck Sharp & Dohme Corp.

Inventor： Blair T. Lapointe ,  Peter H. Fuller ,  Hakan Gunaydin ,  Kun Liu ,  Mark E. Scott ,  B. Wesley Trotter ,  Hongjun Zhang

IPC: C07D403/08 ,  C07D401/12 ,  C07D401/06 ,  C07D491/107 ,  C07D491/048 ,  C07D487/10 ,  C07D487/04 ,  C07D405/12 ,  C07D403/14 ,  C07D403/06 ,  C07D231/56 ,  C07D403/12 ,  A61P19/02

Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

公开(公告)号：US10647705B2

公开(公告)日：2020-05-12

申请号：US16186769

申请日：2018-11-12

Applicant: Merck Sharp & Dohme Corp.

Inventor： Yongxin Han ,  Abdelghani Achab ,  Yongqi Deng ,  Xavier Fradera ,  Craig Gibeau ,  Brett A. Hopkins ,  Derun Li ,  Kun Liu ,  Meredeth A. McGowan ,  Nunzio Sciammetta ,  David Sloman ,  Catherine White ,  Hongjun Zhang ,  Hua Zhou

IPC: C07D405/10 ,  A61K31/4523 ,  A61K45/06 ,  C07D471/04 ,  A61K31/437 ,  A61K31/506 ,  A61K31/4155 ,  C07D305/08 ,  A61K31/337 ,  C07D417/10 ,  A61K31/427 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/4184 ,  C07D405/14 ,  A61K31/444 ,  A61K31/513 ,  C07D413/04 ,  C07D401/04 ,  C07D213/56 ,  A61K31/4418 ,  C07D417/14 ,  A61K31/501 ,  C07D241/12 ,  A61K31/4965 ,  A61K31/4427 ,  C07D263/32 ,  A61P37/00 ,  C07D231/12 ,  A61P35/00 ,  C07D413/10 ,  C07D401/12 ,  C07D405/04 ,  A61P31/00 ,  C07D209/46 ,  C07D413/14

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US10584121B2

公开(公告)日：2020-03-10

申请号：US15770257

申请日：2016-10-27

Applicant: Merck Sharp & Dohme Corp.

Inventor： Hongjun Zhang ,  Kenneth Jay Barr ,  Blair T. Lapointe ,  Hakan Gunaydin ,  Kun Liu ,  B. Wesley Trotter

IPC: C07D471/04 ,  A61K31/4353 ,  A61P37/00 ,  A61P11/06 ,  A61P19/02 ,  A61P29/00

Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

公开(公告)号：US10196354B2

公开(公告)日：2019-02-05

申请号：US15647437

申请日：2017-07-12

Applicant: Merck Sharp & Dohme Corp.

Inventor： Kenneth J. Barr ,  Corey E. Bienstock ,  John K. Maclean ,  Hongjun Zhang ,  Richard T. Beresis ,  Dongshan Zhang ,  Neville J. Anthony ,  Blair T. Lapointe ,  Yuan Tian

IPC: C07D209/26 ,  C07D231/56 ,  C07D471/04 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  A61K31/404 ,  A61K31/416 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/5377 ,  C07D405/12

Abstract: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

公开(公告)号：US20150353498A1

公开(公告)日：2015-12-10

申请号：US14432462

申请日：2013-09-26

Applicant: Xianhai HUANG ,  Anandan PALANI ,  Ashwin U. RAO ,  Hongjun ZHANG ,  Wei ZHOU ,  MERCK SHARP & DOHME CORP.

Inventor： Xianhai Huang ,  Anandan Palani ,  Ashwin U. Rao ,  Hongjun Zhang ,  Wei Zhou

IPC: C07D217/24 ,  C07D401/06 ,  C07D413/14 ,  A61K31/4725 ,  C07D413/04 ,  A61K31/472 ,  A61K31/496

CPC classification number: C07D217/24 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/496 ,  A61K45/06 ,  C07D401/06 ,  C07D401/12 ,  C07D413/04 ,  C07D413/14 ,  A61K2300/00

Abstract: The invention provides certain substituted isoquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters. The invention also provides pharmaceutical compositions comprising for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.

Abstract translation: 本发明提供某些式（I）的取代的异喹啉及其药学上可接受的盐和酯。 本发明还提供药物组合物，其包含用于治疗与不受控制或不适当刺激CRTH2功能相关的疾病或病症。

公开(公告)号：US20150191434A1

公开(公告)日：2015-07-09

申请号：US14421057

申请日：2013-08-14

Applicant: Merck Sharp & Dohme Corp.

Inventor： Kenneth J. Barr ,  John K. Maclean ,  Hongjun Zhang ,  Richard T. Beresis ,  Dongshan Zhang ,  Brian M. Andresen ,  Neville J. Anthony ,  Blair T. Lapointe ,  Nunzio Sciammetta

IPC: C07D231/56 ,  C07D471/04 ,  A61K31/437 ,  C07D403/06 ,  C07D413/06 ,  A61K31/404 ,  A61K31/496 ,  C07D405/12 ,  C07D401/06 ,  A61K31/454 ,  C07D209/26 ,  A61K31/416 ,  A61K31/5377

CPC classification number: C07D231/56 ,  A61K31/404 ,  A61K31/416 ,  A61K31/437 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  C07D209/26 ,  C07D401/06 ,  C07D403/06 ,  C07D405/12 ,  C07D413/06 ,  C07D471/04 ,  Y02A50/409

Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐或溶剂化物。 这些化合物可用于治疗RORGAMMT介导的疾病或病症。